Ridebanevej 9, 1870 Frederiksberg C
The Lykkesfeldt Lab
The Lykkesfeldt Lab studies disease mechanisms and therapy of major life style-associated human conditions by developing, using and refining in vivo experimental models, methods and clinical trials in an ethically and scientifically responsible manner. The Lykkesfeldt Lab trains highly qualified students and junior scientists within pharmacology, toxicology and biomedicine.
Our research and the students and scientists we train have a high international level and contributes globally to evidence-based disease prevention and treatment.
Redox imbalance in development and disease
Living cells are constantly exposed to reactive oxygen and nitrogen species which may lead to modifications of the cellular macromolecules, mutations and eventually cell death. Increased oxidative stress - i.e. an imbalance in the cellular redox homeostasis - is observed during e.g. smoking, aging and inflammation and has been associated with several chronic diseases including atherosclerosis and cancer.
In a variety of studies ranging from primary cells, cell & tissue culture, animal models to clinical trials, we study the effects of oxidative insults on the redox homeostasis as well as the possible benefit of intervention with bioactive compounds to selected groups of animals or humans. Together with measurements of oxidative damage-an effect of oxidative stress-we investigate the link between oxidative stress and various pathological conditions. Our primary goal is to understand the role and mechanism of altered redox status in disease development and thereby pave the road for better prevention strategies and pharmacotherapy for animals and humans. Key projects involve effects of vitamin C deficiency, non-alcoholic fatty liver disease and cardiovascular disease.
2009 to present
Professor in experimental pharmacology and toxicology at Department of Disease Biology, Life Science Faculty, University of Copenhagen.
Professor in biotechnology at Department of Disease Biology, Life Science Faculty, University of Copenhagen.
1998 to 2007
Associate professor in pharmacology at Department of Veterinary Pathobiology, Royal Veterinary and Agricultural University.
1996 to 1998
Visiting Scientist at Department of Molecular and Cell Biology, University of California, Berkeley, USA
1993 to 1995
Post doctoral fellow at Department of Pharmacology, University of Copenhagen.
1990 to 1992
Ph.D. student at the Plant Biochemistry Laboratory, Royal Veterinary and Agricultural University.
D.Sc. in Medicine from the University of Copenhagen, Denmark. Title of thesis: Vitamin C as biomarker and treatment of oxidative stress caused by smoking - Methodological and clinical studies.
Ph.D. in Biochemistry from the Technical University of Denmark. Title of thesis: The biosynthesis of cyanogenic glucosides and glucosinolates in higher plants.
M.Sc. in Organic Chemistry and Chemistry of Natural Products from the Technical University of Denmark. Title of thesis: The synthesis of alfa,beta-unsaturated delta-lactones.
Search Pubmed for Jens Lykkesfeldt
In vivo Pharmacology
Dr. Lykkesfeldt is head of the In Vivo Pharmacology PhD program. Read more on the homepage www.invivofarm.dk
The LIFEPHARM Centre
Dr. Lykkesfeldt is Director of the LIFEPHARM Centre for In Vivo Pharmacology. Read more on the homepage www.lifepharm.dk
Declaration of Interest Statement
Dr. Lykkesfeldt does not own stocks or stock options in any company.
Dr. Lykkesfeldt is founding director of the Lifepharm Centre, which is partly funded by Novo Nordisk A/S. He has present or former collaborations with and has received funding from Novo Nordisk, H. Lundbeck, Nordic Bioscience, Chr. Hansen, has been consultant for Novo Nordisk and Chr. Hansen and has received travel reimbursement from DSM.
Dr. Lykkesfeldt is Deputy Editor-in-Chief of and receives a minor annual honorarium from 'Basic and Clinical Pharmacology and Toxicology', serves on editorial boards of journal 'Antioxidants' and 'In Vivo' and is member of American Society of Nutrition, European Atherosclerosis Society, Society for Radical Bioogy and Medicine, and Danish Society of Toxicology, Pharmacology and Medicinal Chemistry.
Dr. Lykkesfeldt is elected member of the Academic Council at SUND and appointed menber of the UCPH Senate and the UCPH Practice Committee